Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon alpha-2a - Amarillo/Hayashibara

Drug Profile

Interferon alpha-2a - Amarillo/Hayashibara

Alternative Names: IFN-alpha lozenges; MOR 22; Natural human lymphoblastoid interferon-alpha; Veldona

Latest Information Update: 28 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hayashibara
  • Developer Amarillo Biosciences; CytoPharm; Hayashibara; Mochida Pharmaceutical; NOBEL ILAC; Otsuka Pharmaceutical
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunomodulators; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Human papillomavirus infections; Polycythaemia vera; Behcet's syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B; Hepatitis C; Myeloid leukaemia; Renal cell carcinoma
  • Phase II Influenza virus infections
  • No development reported Behcet's syndrome; Solid tumours; Thrombocytopenia
  • Discontinued Chronic obstructive pulmonary disease; Fibromyalgia; HIV infections; Human papillomavirus infections; Liver cancer; Polycythaemia vera; Pulmonary fibrosis; Sjogren's syndrome; Skin disorders; Thrombocytosis

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for clinical-Phase-Unknown development in Thrombocytopenia in USA (PO, Lozenge)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in USA (PO, Lozenge)
  • 03 Aug 2017 Amarillo Biosciences files for second Continuation Application with the USPTO for low-dose oral interferon alpha in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top